These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33502733)

  • 1. Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis.
    Peralta MF; Usseglio NA; Bracamonte ME; Guzmán ML; Olivera ME; Marco JD; Barroso PA; Carrer DC
    Drug Deliv Transl Res; 2022 Jan; 12(1):180-196. PubMed ID: 33502733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
    Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
    Neira LF; Mantilla JC; Escobar P
    J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
    Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
    Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
    Ribeiro JBP; Miranda-Vilela AL; Graziani D; Gomes MRA; Amorim AAS; Garcia RD; de Souza Filho J; Tedesco AC; Primo FL; Moreira JR; Lima AV; Sampaio RNR
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():282-290. PubMed ID: 26306406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
    Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy offers a novel approach to managing miltefosine-resistant cutaneous leishmaniasis.
    Cabral FV; Riahi M; Persheyev S; Lian C; Cortez M; Samuel IDW; Ribeiro MS
    Biomed Pharmacother; 2024 Aug; 177():116881. PubMed ID: 38917757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
    Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
    J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
    Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
    Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of ketoconazole formulations for topical use in cutaneous leishmaniasis caused by Leishmania (Viannia)].
    Vera AM; Casadiego OA; Mantilla JC; Escobar P
    Rev Peru Med Exp Salud Publica; 2018; 35(3):476-482. PubMed ID: 30517509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
    Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
    Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
    Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
    Van Bocxlaer K; Dixon J; Platteeuw JJ; Van Den Heuvel D; Mcarthur KN; Harris A; Alavijeh M; Croft SL; Yardley V
    J Antimicrob Chemother; 2023 Jul; 78(7):1723-1731. PubMed ID: 37229566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.
    Emiliano YSS; Almeida-Amaral EE
    J Nat Prod; 2018 Aug; 81(8):1910-1913. PubMed ID: 30095915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical photodynamic therapy with chloroaluminum phthalocyanine liposomes is as effective as systemic pentavalent antimony in the treatment of experimental cutaneous leishmaniasis.
    Lopes SC; Silva RA; Novais MV; Coelho LD; Ferreira LA; Souza PE; Tedesco A; Azevedo RB; Aguiar MG; Oliveira MC
    Photodiagnosis Photodyn Ther; 2019 Dec; 28():210-215. PubMed ID: 31454712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.